ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0313

Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease?

Katja Perdan Pirkmajer1, Matija TOMSIC1 and Alojzija Hocevar2, 1University Medical Centre Ljubljana, Ljubljana, Slovenia, 2UKC Ljubjana, Ljubjana, Slovenia

Meeting: ACR Convergence 2021

Keywords: Sjögren's syndrome, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Ultrasonographically depicted morphological changes of major salivary glands (SG) have been recently correlated with the disease activity in primary Sjögren’s (pSS)1. The aim of our prospective, cross-sectional study was to determine whether pSS patients with normal SG ultrasound indeed have less active disease at baseline.

Methods: We included 129 consecutive adult pSS patients, diagnosed at our secondary – tertiary center between 2017-2019. All patients fulfilled the 2016 ACR/EULAR classification criteria2 and underwent a routine diagnostic procedure including major SG ultrasound3 and minor SG biopsy. Disease activity was assessed with ESSDAI4. Multivariate logistic regression was used to evaluate factors predicting baseline ESSDAI.

Results: Our pSS cohort consisted of 120 females and 9 males, with a median (IQR) age 62 (51-69) years, and median (IQR) symptom duration of 24 (10-41) months. Among them 95 (73.6 %) had antinuclear antibodies, 98 (76.0%) anti-SSA, 21 (16.3%) had anti-SSB, and 37 (28.6%) had rheumatoid factor (RF), respectively. Four patients had anticentromere antibodies. Twenty-nine (22.5%) patients had 3 or more different autoantibodies. Minor salivary gland biopsy was positive in 83 (64%) patients. Forty-nine patients (38.0%) had a positive major SG ultrasound. Median (IQR) ESSDAI was 2 (0-6), range 0-34 at baseline. Among the ESSDAI components articular and biological component predominated (Figure 1). Using multivariate analysis, we found no association between baseline ESSDAI, and SG US changes, histological focus score, the number of antibodies, patients’ age, sex, symptom duration time, inflammatory parameters (ESR and CRP). The single parameter that predicted baseline ESSDAI was the presence of RF (P < 0.001). Only anti-SSB (p=0.004)) and antinuclear antibodies (p=0.003) emerged as predictors of positive SG ultrasound.

Conclusion: Our results imply that SG US does not predict baseline pSS disease activity, determined by ESSDAI.

References: 1. Milic V, et al. PLoS One 2019. doi: 10.1371/journal.pone.0226498. 2. Shiboski CH et al. Arthritis Rheumatol 2017. doi: 10.1136/annrheumdis-2016-210571.3. Hocevar A et al. Rheumatology (Oxford) 2005. doi: 10.1093/rheumatology/keh588.4. Seror R, et al. ARD 2010. doi: 10.1136/ard.2009.110619corr1.

Figure 1: ESSDAI by components in our pSS cohort.


Disclosures: K. Perdan Pirkmajer, None; M. TOMSIC, None; A. Hocevar, None.

To cite this abstract in AMA style:

Perdan Pirkmajer K, TOMSIC M, Hocevar A. Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease? [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/do-primary-sjogrens-syndrome-patients-with-normal-major-salivary-gland-ultrasound-have-less-active-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-primary-sjogrens-syndrome-patients-with-normal-major-salivary-gland-ultrasound-have-less-active-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology